Risankizumab is used for the treatment of moderate to severe active Crohn's disease (CD) in adults who have had an inadequate response, loss of response, or intolerance to conventional therapy or biologic agents; it is also used in research on immune-mediated and inflammatory diseases, including plaque psoriasis, psoriatic arthritis, generalized pustular psoriasis, and erythrodermic psoriasis.